Patient level micro simulation model for evaluating the future potential cost effectiveness of pharmacy based interventions in the control and management of diabetes related complications in Canada

Background: The increased risk of complications among diabetes patients poses a serious threat to population health. Pharmacy-based interventions can decrease the burden of diabetes and its related complications. This study evaluates the cost-effectiveness of pharmacy-based interventions and offers insights on the practicality of their adoption by health practitioners. Methods: We developed population-based micro-simulation model using 2,931 patients with diabetes in Canada .We used the risk equations on the UK Prospective Diabetes Study (UKPDS) to estimate the incidence and mortality of four of the most common diabetes-related complications (heart failure, stroke, amputation, and blindness). We extrapolated the potential effects of pharmacy interventions on reducing time-varying risk factors for diabetes complications. Cost was quantified as the annual cost of complications; and, the cost associated with pharmacy-based interventions. The final outcomes were the incremental costs per quality-adjusted life years (QALY) gained. Both deterministic and probabilistic sensitivity analysis were conducted to examine the robustness of the ratio. Result: Pharmacy-based interventions could prevent 155 preventable deaths, 159 strokes, 29 cases of blindness, 24 amputations, and 19 heart failures across the lifetime of 2,931 patients. In addition, an estimated 953 QALYs (0.32 per patient) would be gained among the intervention group. Per QALY, the incremental discounted cost is $3,928, suggesting that pharmacy-based interventions are likely cost-effective compared to usual care. At an ICER threshold of $50,000, over 92% of the simulation remains cost-effective. Conclusion: Pharmacist-based interventions targeted at addressing the development of diabetes-related complications among Canadian patients have the potential to offer a cost-effective strategy.


Introduction
Diabetes mellitus (DM) is one of the most prevalent non-communicable diseases worldwide, and poses a major problem to the 21 st century health system (1,2). Perhaps most threatening about DM is its unprecedented growth: In less than three decades, the number of adults diagnosed with diabetes has doubled (2). This translates to over 400 million people living with diabetes today, and an estimated 642 million who will live with diabetes by 2040 (3). In many developed countries, diabetes is a leading cause of death, and was the culprit behind at least 1.3 million deaths in 2013 alone (4). Diabetes is also associated with a number of complications, including: cardiovascular disease, nephropathy, neuropathy, amputations, and blindness (5)(6)(7)(8). These complications lead to premature death, reduce individuals' quality of life, and place a heavy global economic burden on the whole of society to the tune of US$548 billion each year (3,(5)(6)(7)(8).
This cost is not limited to the health care system, but also includes indirect costs incurred by loss of productivity resulting from disability and/or premature death (9). Unfortunately, the prognosis in Canada is not much better. In comparison to the general population, diabetes patients are three times more likely to be hospitalized for cardiovascular disease, twelve times more likely to be hospitalized for end-stage renal disease, and twenty times more likely to be hospitalized for a non-traumatic lower limb amputation (11,12). This means that, of the Canadian healthcare dollars being expended on diabetes patients, eighty percent are incurred as a result of diabetesrelated complications (10). However, there is an opportunity to reduce this expenditure through the adoption of diabetes management interventions such as pharmacy-based ones. Pharmacybased interventions include a wide range of services, all with the common aim of giving diabetes patients greater control and management over their disease. Common examples of pharmacybased interventions include: consultations with pharmacists; patient education about selfmonitoring and self-management techniques; preventive programming that emphasizes lifestyle modifications; reminders about annual physical examinations; assistance with adherence to medication; patient education about the correct use of insulin, anti-hyperglycemic medications and oral hypoglycemic agents; and, programming that increases patients' awareness about effective diabetes management (13)(14)(15)(16)(17). Recent reviews of pharmacy-based interventions have without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint demonstrated that they have a positive impact on clinical outcomes (13)(14)(15)(16)(17). These findings are promising, especially because they suggest that pharmacy-based interventions could reduce diabetes-related complications, morbidity and mortality (13)(14)(15)(16)(17). Rising health care costs, limitations on available health care resources, and debates over the comparative effectiveness of diabetes management strategies has led to an increased interest in developing analytic models that can evaluate the future potential cost-effectiveness of such intervention. These models compliment clinical trials, which typically provide data on intermediate outcomes like HbA1c, SBP, and LDL. Data from clinical trials can then be used to populate analytic models, and provides a basis for predicting long-term health outcomes, like life-years saved or QALYs gained.
This study aims to evaluate the future potential cost effectiveness of pharmacy-based interventions for diabetes management in Canada. In order to conduct this evaluation, we estimate life time outcome and quality-adjusted life expectancy among diabetes patients who experience diabetes-related complications (heart failure, stroke, amputation, and blindness) or diabetes-related death.

Model Overview
We evaluated the future potential cost-effectiveness of pharmacy-based interventions for patients with diabetes compared to usual care. Intermediate outcome of intervention were modeled as reduction of hemoglobin A1C (HbA1c) level, body mass Index (BMI), systolic blood pressure (SBP), and low-density lipoproteins (LDL) as most important risk factors of four common diabetes-related complications including heart failure, stroke, amputation and blindness. Cost was quantified as the annual cost of heart failure, stroke, amputation and/or blindness among diabetes patients; and, the cost associated with pharmacy-based interventions borne by society.
To fully capture the effect of the intervention, we extrapolated the potential effects of intervention in relation to cost, health outcomes, and health-related quality of life (HRQoL) over the next 50 years by calculating the incremental cost per QALY gained of pharmacy-based intervention versus usual care in base case scenario. This model considered both costs and health without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed  Figure (1).

Model Structure
Using Anylogic software package 8.2.3, a hybrid simulation model was developed, which included agent-based and system dynamics. Agent-based modeling (ABM) enables to simulate more complex interactions and processes associated with chronic disease. Thus, this technique is very suitable for incorporating individuals with different risk factors and health behavior characteristic and evaluating the impact of adjusting risk factors on the better control and management of diabetes (19).We captured four major diabetes-related complications progresses among patients with heterogeneous characteristics through state-transition formalism as state charts in ABM model. Also, we used a system-dynamic approach to estimate accumulated costs and QALYs over time ( Figure A1-A2 in appendix).
The simulation model mimicked a multistage study and was populated by data from the Survey on Living with Chronic Diseases in Canada (SLCDC). This data was used to build an individual-level micro-simulation model predictive of diabetes-related complications (heart failure, stroke, blindness, and amputation) and death, and the associated health care cost and QALYs in the presence and absence of pharmacist-based intervention. Within the model, a set of attributes known to be associated with diabetes-related complications was assigned to each person. The attributes were also subject to a set of rules (i.e. transition probabilities) and states reward (i.e. cost and utility). All parameters are shown in Table (1). without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03.10.20033597 doi: medRxiv preprint

Diabetes Risk Factors
To estimate a diabetes patient's progression from complication free to a complication ridden  Table A1). For some of the risk questions which the corresponding baseline variables were not available in the SLCDC survey, we estimated baseline variables based on age and sex specific.

Mortality
To estimate progression from a complication-free state to a state where at least one of the four major complications or death have occurred, our analysis considered four equations for without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed   Table A2).

Treatment Effect
The impact that pharmacy-based interventions have on four major risk factors associated with diabetes-related complications was extracted from recent systematic reviews and metaanalyses. The four major risk factors include: HbA1c, BMI, SBP, and LDL.

Hemoglobin (HbA1c)
From baseline to the last follow-up 12 months later, the standardized absolute mean difference in the reduction of HbA1c was significantly more favorable in the pharmacy-based intervention group, then in the control group (0.96%; 95% CI 0.71:1.22, P<0.001) (13).

Body Mass Index (BMI)
From baseline to the last follow-up 12 months later, the standardized absolute mean difference in the reduction of BMI units was 0.61 (95% CI 0.20: 1.03, P=0.000) in favor of the pharmacybased intervention group (13).

Systolic Blood Pressure (SBP)
In comparison to the control group, there were significant reductions in SBP among diabetes patients in the pharmacy-based intervention group after a 12-month period (-6.2 mmHg [95% CI -7.8 to -4.6]) (17). without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint

Low Density Lipoprotein (LDL) Cholesterol
In comparison to the control group, there were significant reductions in LDL cholesterol among diabetes patients in the pharmacy-based intervention group after a 12-month period (-11.7 mg/dL [-15.8 to -7.6]) (17).

Health Utilities
We assumed that utility values derived from the American population are relevant to the Canadian population. We quantified HRQoL for a set of health states of interest based on American catalogue of EQ-5D utility values (21). Health states of interest include: following a stroke, following heart failure, after the age of 70 years. Following a stroke, the resulting utility was 0.694. Following heart failure, the resulting utility was 0.636. After the age of 70, a utility decrement of 0.00029 per year was applied to all years.
Under the assumption that utility values derived from the United Kingdom population are relevant to Canada, the UKPDS outcome model was used to estimate HRQoL for a set of health states of interest. Health states of interest include following an amputation, and following blindness. Following amputation, a utility decrement of 0.520 was applied. Following blindness, a utility decrement of 0.726 was applied. A weight of zero was assigned to death. If applicable to incorporate the effect of concurrent complications, a multiplicative method approach was applied (21).

Cost of treating diabetes-related complications
Health care resource utilization and their costs associated with the management of diabetesrelated complications were extracted from the Ontario Ministry of Health and Long-Term Care (22). Total costs of patients with diabetes and patients with complications were quantified in terms of hospitalizations, outpatient visits, emergency visits, home care and long-term management costs. Costs were inflated to the value of the 2016 Canadian dollar using the health without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint component of the Canadian Consumer Price Index. On average, the annual cost for patients without diabetes-related complications was $2,075 (22). The estimated costs for each of the four diabetes-related complications in the first year they occur, and for all subsequent years are shown in Table (1).

Intervention Costs
To estimate the cost of pharmacy-based interventions, costs incurred by the implementation of the MedsCheck program served as a benchmark. This program is a pharmacy-based intervention targeted at diabetes patients in Canada (23). Based on the current fee schedule of the MedsCheck program in Alberta, the unit cost of the first annual consultation was determined to be $75 CAD, the unit cost of each subsequent consultation within that year was $25 CAD, and the unit cost of long-term follow-up was $75 CAD (23).
The indirect costs associated with wait-times and travelling related to pharmacy-based interventions were added to the model. Based on the MedsCheck program, the total time lost for pharmacy consultation was 2 minutes for waiting and 20 minutes for the duration of the consultation (24). Based on these estimates, we calculated an opportunity cost. The total time lost was multiplied by the number of pharmacy consultations in one year assuming that the entire study population would be the recipient of pharmacy-based interventions. This number was then multiplied by $24.96 CAD or the average wage per hour in Canada (25).
Based on data from Geographic Accessibility of Community Pharmacies, the cost of travelling to a pharmacy was estimated using the average travel time among patients who visited a pharmacist (26), and the mean fuel cost per kilometer (km) of $0.12/km CAD (27).

Cost-effectiveness analysis
An incremental analysis combined the joint estimates of costs and effects across the baseline scenario and the intervention scenario. The result of this analysis yielded the point estimate of the mean ICER. The ICER was calculated as the difference in costs between baseline and intervention divided by the difference in effects (i.e. QALYs) between baseline and intervention. without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint Measures of variance for the joint incremental costs and effects were obtained using Monte Carlo simulation and presented graphically using the cost-effectiveness plane. In order to convert health outcome (QALYs) to common metric as dollar, the net monetary benefit (NMB) was calculated. The NMB is equal to the incremental QALYs multiplied by the ceiling ratio (CR) of willingness to pay (WTP) per QALY minus the incremental costs.

Sensitivity Analysis
Both probabilistic and deterministic sensitivity analyses were conducted to explore the model's

Results
The primary objective of the simulation model was to calculate the accumulated events of four diabetes-related complications over the lifetime of 2,931 patients with specific baseline characteristics and risk factors. As shown in Table 4 in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed Despite changes to the ICERs across the one-way sensitivity analyses, the pharmacy-based intervention remained cost-effective. When the lifetime horizon was shortened to 20 years, the ICER changed to $2,831.9 CAD. When the lifetime horizon was shortened to 20 years and a 1.5% discount was applied to costs and effects, ICER changed to $4,923. When the anticipated effect of the intervention on HbA1c, BMI, LDL, and SBP was lowered, ICER changed to $4,580 (Table 2).
Our probabilistic sensitivity analyses involved varying all of the parameters' uncertainties at the same time using Monte Carlo simulation. Then, 10,000 samples of cost and QALYs were used for both the usual care and intervention groups ( Figure 2). As shown in the cost-effectiveness acceptability curve plot, 92% of iterations remained within a cost-effectiveness threshold of $50,000 per QALY (Figure 3). in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose

Discussion
Using a patient-level micro-simulation model, the future potential cost-effectiveness of pharmacy-based intervention in the control and management of four diabetes-related complications was analyzed. Across a 50-year lifetime horizon, the intervention proved to be a cost-effective strategy when compared to the usual care (status quo) diabetes patients across Canada receive. The ICER remained below the cost-effectiveness threshold across both deterministic and probabilistic sensitivity analyses. This suggests that the implementation of pharmacy-based interventions could yield consistent results. This consistency is encouraging, especially in the context of the Canadian health care system where pharmacists' scope is impacted by the jurisdiction in which they practice (36-37).
The treatment effect of pharmacy-based interventions was assumed to be low in our analysis.
The effect on HbA1c, BMI, SBP and LDL was set at 0.71, 0.20, 4.6, and 7.6 respectively. Based on these values, the intervention resulted in the addition of 670 more QALYs compared to status quo. Our analysis included a wide range of services that made up an integrated pharmacy-based intervention. However, the results of a recent meta-analysis suggest that diabetes education delivered by pharmacists coupled with pharmaceutical care maximizes the effectiveness of such services (28). HbA1c was lowered by 0.86 and SBP was lowered by 4.94 when this scheme was followed (28). When our model was adjusted in accordance with this specific type of pharmacybased intervention, the result did not change. Further research must be conducted to corroborate these findings, but this result suggests that pharmacy-based intervention could be effective in even the most resource limited settings.
Our results did change, however, when the discount rate and time horizon were reduced. In these scenarios, the pharmacy-based intervention group gained 1,031 and 1,112 QALYs respectively.
These results highlight that this interventions will operate across jurisdictions and across patient lifespans. without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint Our findings add to the literature and support previous economic evaluations of simulated community care programs for diabetes patients in Canada and around the world. Another Canadian patient-level microsimulation mode, the Ontario Diabetes Economic Model (ODEM), suggested that the incremental cost-effectiveness per QALY of a multidisciplinary management program was $5,203 over 10 years (22). Pharmacy-based interventions have also proven to be cost-effective in reducing risk factors, like hypertension, associated with diabetes-related complications in Canadian patients (29). This mirrors the reductions in risk factors reported in the present study. Further, a Markov cost-effectiveness model evaluated pharmacy-based interventions in Kaiser Permanente Northern California and results demonstrated saving of $6,364 over the lifetime of a single diabetes patient; prevent cardiovascular disease among diabetes patients; and, is less expensive and more effective than usual care over a 10-year time span (30). Again, these positive results compliment the findings from present study. By adding to this literature, provincial governments and health professionals are given a source from which to draw when creating evidence-based practices for the treatment of diabetes patients.
Additionally, our findings compliment previous economic evaluations conducted in real time using emerging patient data. Over 36-months, a randomized controlled clinical trial estimated the ICER per QALY of pharmaceutical care used to manage diabetes and hypertension among elderly patients (31). This analysis demonstrated that pharmaceutical care did not significantly increase the cost of direct health care, but did significantly improve health outcomes (31). More specifically, the ICER per QALY ($53.50) gained reflected favorably on its cost-effectiveness (31).
In a North American context, the cost-effectiveness of pharmacy-led drug management education programs (DMEP) has been evaluated. Results from these evaluations suggest that DMEPs are cost-effective relative to usual care, and avert $39 USD per day spends on glycemic symptoms among diabetes patients (32). The results from our simulated model are consistent with findings from clinical trials, and operational education programs. This consistency reinforces the idea that pharmacy-based interventions could be an effective means to manage diabetes and its related complications. without crediting the original authors.
in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) .
Lastly, our findings do not vary even when compared to the results yielded by different modeling techniques. When a discrete-event simulation model was used, alternative treatment strategies, like pharmacy-based interventions, were associated with enhanced long-term health outcomes among diabetes patients (33). Similarly, when a Markov cohort analysis was conducted to assess

Conclusion
In conclusion, Canadian health policy makers should afford consideration to pharmacy-based interventions in the management of diabetes and its related complications. Through the expansion of education-based services by community pharmacies, there is the potential to reduce the incidence of diabetes-related complications, and death resulting from diabetes. This is an important avenue that should not be overlooked, especially because it offers a solution to the growing and complex problems caused by diabetes. in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03.10.20033597 doi: medRxiv preprint in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed  in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed  in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed  in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed The Weibull model of UKPDS for heart failure in table D assumes a baseline hazard given by: And in the proportional hazards model; The parameters requiring calculation are λ, βj and p, which are given in Table D; time at risk (t) in the model is duration of diabetes. The unconditional probability of heart failure occurring between time t and t+1 can be estimated using the integrated hazard. The integrated hazard at time t is: And the unconditional probability of heart failure in the interval t to t+1 is: For example the calculation of the probability of heart failure in the current year for a one patient record in SLCDC with following characteristic (male, 70 years of age, with 8 years of diabetes, LDL 3.0 mmol/l, BMI of 32, eGFR 50, with microalbuminuria and a history of amputation) estimated as below: in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed  in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose

Appendix II) Estimating the Probability of death in the 1st year of complication/s and no history of events
The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint Following descriptions derived from the supplementary material of United Kingdom Prospective Diabetes model (UKPDS2) (1) Probability of death in the 1st year of complication/s and no history of events: Logistic regression was used to model mortality in the year of an event. The probability of survival is given by; S = − 1 + − Where z = + 1 1 + 2 2 + 3 3 + ⋯

Current year MI
As an example, using the coefficients in Table E, for a one patient record in SLCDC with following characteristic (70 year-old male smoker with 12 years of diabetes, heart rate 80 bpm, has an MI but has no history of other events) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint The parameters required are λ, βj and ɸ, which are given in table E; time at risk (t) in the model is current age. The probability of death occurring between time t and t+1 can be estimated using the integrated hazard. The integrated hazard at time t is: And the unconditional probability of death in the interval t to t+1 is: As an example, using the coefficients in Table E, for a patient record in SLCDC with following characteristics (a 70 year-old male smoker with 12 years of diabetes, who is overweight, has a white blood cell count of 6x106/ml and a history of heart failure but no events in the current year) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose The copyright holder has placed this preprint (which was not peer-reviewed) . https://doi.org/10.1101/2020.03. 10.20033597 doi: medRxiv preprint